《Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening》 was published in Journal of Medicinal Chemistry in 2020. These research results belong to Wellaway, Christopher R.; Amans, Dominique; Bamborough, Paul; Barnett, Heather; Bit, Rino A.; Brown, Jack A.; Carlson, Neil R.; Chung, Chun-wa; Cooper, Anthony W. J.; Craggs, Peter D.; Davis, Robert P.; Dean, Tony W.; Evans, John P.; Gordon, Laurie; Harada, Isobel L.; Hirst, David J.; Humphreys, Philip G.; Jones, Katherine L.; Lewis, Antonia J.; Lindon, Matthew J.; Lugo, Dave; Mahmood, Mahnoor; McCleary, Scott; Medeiros, Patricia; Mitchell, Darren J.; O’Sullivan, Michael; Le Gall, Armelle; Patel, Vipulkumar K.; Patten, Chris; Poole, Darren L.; Shah, Rishi R.; Smith, Jane E.; Stafford, Kayleigh A. J.; Thomas, Pamela J.; Vimal, Mythily; Wall, Ian D.; Watson, Robert J.; Wellaway, Natalie; Yao, Gang; Prinjha, Rab K.. Quality Control of tert-Butyl 4-aminopiperidine-1-carboxylate The article mentions the following:
The bromodomain and extraterminal (BET) family of bromodomain-containing proteins are important regulators of the epigenome through their ability to recognize N-acetyl lysine (KAc) post-translational modifications on histone tails. These interactions have been implicated in various disease states and, consequently, disruption of BET-KAc binding has emerged as an attractive therapeutic strategy with a number of small mol. inhibitors now under investigation in the clinic. However, until the utility of these advanced candidates is fully assessed by these trials, there remains scope for the discovery of inhibitors from new chemotypes with alternative physicochem., pharmacokinetic, and pharmacodynamic profiles. Herein, we describe the discovery of a candidate-quality dimethylpyridone benzimidazole compound which originated from the hybridization of a dimethylphenol benzimidazole series, identified using encoded library technol., with an N-Me pyridone series identified through fragment screening. Optimization via structure- and property-based design led to I-BET469, which possesses favorable oral pharmacokinetic properties, displays activity in vivo, and is projected to have a low human efficacious dose. In addition to this study using tert-Butyl 4-aminopiperidine-1-carboxylate, there are many other studies that have used tert-Butyl 4-aminopiperidine-1-carboxylate(cas: 87120-72-7Quality Control of tert-Butyl 4-aminopiperidine-1-carboxylate) was used in this study.
tert-Butyl 4-aminopiperidine-1-carboxylate(cas: 87120-72-7) belongs to anime. Hydrogen peroxide (H2O2) and peroxy acids generally add an oxygen atom to the nitrogen of amines. With primary amines, this step is normally followed by further oxidation, leading to nitroso compounds, RNO, or nitro compounds, RNO2. Secondary amines are converted to hydroxylamines, R2NOH, and tertiary amines to amine oxides, R3NO.Quality Control of tert-Butyl 4-aminopiperidine-1-carboxylate
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem